CHRISTOPHER CARSON: Open Payments
NPI 1578986915 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$534 in 16 payments from 7 companies in 2025. Trend: 2023 $125 · 2024 $222 · 2025 $534
Food & beverage: $534
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $170 |
| Otsuka America Pharmaceutical, Inc. | 3 | $155 |
| Alkermes, Inc. | 3 | $80 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: Ozempic, ABILIFY MAINTENA, Auvelity, ARISTADA, REXULTI, LYBALVI, FANAPT, CAPLYTA.
Industry payments across MS — which companies pay providers there.
